A 2026 EEG-ECG preprint reported that beta efficiency-sympathetic coupling differed across healthy young adults, healthy older adults, and Parkinson’s disease patients, p = 0.0032, while gamma efficiency-sympathetic coupling differed at p = 0.0003.1 The main claim is that motor, cognitive, and autonomic physiology may be coupled tightly enough to deserve biomarker-level study. Research Highlights Brain-heart …
A 2026 medicinal-chemistry study found that thymol carbamate TC-6 inhibited human butyrylcholinesterase at 3.6 nM, showed more than 2,500-fold selectivity over human acetylcholinesterase, crossed a blood-brain-barrier screening assay, and improved spatial-memory behavior in amyloid-β-injected mice. Research Highlights TC-6 hit BuChE hard: Wu et al. reported human butyrylcholinesterase (BuChE) inhibition at 3.6 nM, compared with 9,320 …
A 2026 Journal of Neuroinflammation study involving 33 people with multiple sclerosis and 10 healthy controls found disease-specific B-cell repertoire signatures even when ordinary B-cell subset counts looked modest, then showed that most disease-modifying therapies shifted repertoire diversity after 6 months. Research Highlights Repertoire sequencing found MS signal: Vasilenko et al. analyzed more than 196,100,000 …
A 259-person multiple system atrophy survey found diagnosed neurogenic orthostatic hypotension in 41.7% of respondents, while another 40.0% had upright symptoms suspicious for nOH without a diagnosis and 21.2% reported never having upright blood pressure measured.1 The operational problem is simple: in MSA, low blood pressure on standing can be disabling, missed, and still undertreated …
A 2026 descriptive study documented 24 major cultural adaptations to the New York University Caregiver Intervention-Enhanced Support (NYUCI-ES) for Chinese and Korean American dementia caregivers. The work is not an outcomes report yet; it is a careful map of how an evidence-based caregiver intervention had to change before it could plausibly fit East Asian immigrant …
A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved hard: negative predictive value fell from 0.831 inside ADNI to 0.644 when the ADNI-trained model was applied to A4.1 Research Highlights 1,707-person ADNI/A4 test: researchers trained amyloid PET prediction models …
Lecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, compared with 12.1 years for amyloid PET signal.1 Research Highlights 0.5-year rebound for Aβ42/40: Bhagunde et al. estimated that half of the Aβ42/40 treatment effect …